Medplus Health Services Limited — PPTs, 02-08-2025: Investor Presentation

Here's a summary of the attached document:

**Financial Highlights:**

MedPlus reported Q1 FY26 revenue of **₹1,542.6 Cr** (+3.6% YoY) with 26.1% gross margin. Operating EBITDA reached **₹72.8 Cr** (4.7% margin), and net profit surged 195.2% YoY to **₹42.34 Cr**. Operating cash flow was **₹187.2 Cr**. Mature stores achieved 10.9% EBITDA margin and 59.8% ROCE, with working capital at 59 days.

**Strategic Initiatives & Growth Drivers:**

Growth strategy prioritizes deeper penetration in existing clusters and leveraging omni-channel for broad reach and quick delivery. Expanding the high-margin private label portfolio is also a key initiative.

**Business Developments:**

MedPlus net added 101 stores in Q1 FY26, bringing its total to 4,813 outlets. This expansion, favoring non-Tier-One cities, reinforces its market footprint and omni-channel capabilities.

**Market Position & Competitive Advantage:**

As the 2nd largest pharma retailer, MedPlus's 4,800+ store network and cluster-based omni-channel model provide a cost-efficient edge. Its hyperlocal presence enables rapid delivery for both acute and chronic segments.

**Investor Implications:**

Results indicate positive growth potential from robust financials and strategic execution. Strong cash flow and focus on private labels/omni-channel position MedPlus for sustained market share gains and margin improvement.